July 11, 2017 / 12:14 PM / 17 days ago

BRIEF-Kadmon announces interim phase 2 data of KD025 in chronic graft-versus-host disease

1 Min Read

July 11 (Reuters) - Kadmon Holdings Inc

* Kadmon announces interim Phase 2 data of KD025 in chronic graft-versus-host disease

* Kadmon Holdings Inc - ‍overall response rate of 71%, with a favorable safety profile in its ongoing phase 2 clinical trial evaluating KD025​

* Kadmon holdings - ‍to date,no drug-related serious adverse events been recorded,no drug-related elevations in liver function tests been observed in study​

* Kadmon - ‍majority of patients in first cohort been able to reduce steroid doses,indicating kd025 potentially offers well-tolerated treatment option for cgvhd patients​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below